About Kindred Biosciences (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book2.95
Return on Equity-38.00%
Return on Assets-36.29%
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) posted its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.02. View Kindred Biosciences' Earnings History.
Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2018?
6 brokers have issued twelve-month price targets for Kindred Biosciences' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Kindred Biosciences' stock price to reach $10.10 in the next year. View Analyst Ratings for Kindred Biosciences.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Sinovac Biotech (SVA), Aurinia Pharmaceuticals (AUPH), Zealand Pharma A/S (ZLDPF), Synergy Pharmaceuticals (SGYP), Cytokinetics (CYTK), SIGA Technologies (SIGA), Inovio Pharmaceuticals (INO), Zealand Pharma A/S - American Depositary Shares (ZEAL), PDL Biopharma (PDLI), Pharma Mar (PHMMF), Paratek Pharmaceuticals (PRTK), Protagonist Therapeutics (PTGX), Kala Pharmaceuticals (KALA), GTX (GTXI), Stemline Therapeutics (STML), Depomed (DEPO), Syros Pharmaceuticals (SYRS) and resTORbio (TORC).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Wendy Wee, Chief Financial Officer (Age 64)
- Denise M. Bevers, Chief Operating Officer, Secretary (Age 47)
- Hangjun Zhan, Chief Scientific Officer
- Herbert D. Montgomery, Independent Director (Age 68)
- Raymond Townsend, Independent Director (Age 70)
- Ervin Veszpremi, Independent Director (Age 56)
Has Kindred Biosciences been receiving favorable news coverage?
Media stories about KIN stock have been trending very positive on Wednesday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.56 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ariel Investments LLC (6.94%), BlackRock Inc. (3.96%), Renaissance Technologies LLC (2.58%), General American Investors Co. Inc. (2.23%), Wells Fargo & Company MN (1.30%) and Deutsche Bank AG (0.49%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which institutional investors are selling Kindred Biosciences stock?
KIN stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Renaissance Technologies LLC, Deutsche Bank AG, General American Investors Co. Inc., C M Bidwell & Associates Ltd. and Wolverine Trading LLC. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Which institutional investors are buying Kindred Biosciences stock?
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $8.85.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $248.06 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (KIN)MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kindred Biosciences (NASDAQ:KIN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.67||2.67||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$10.10||$9.90||$9.90||$9.00|
|Price Target Upside: ||14.12% upside||3.13% upside||20.73% upside||29.50% upside|
Kindred Biosciences (NASDAQ:KIN) Consensus Price Target History
Kindred Biosciences (NASDAQ:KIN) Analyst Ratings History
(Data available from 3/21/2016 forward)
Kindred Biosciences (NASDAQ:KIN) Earnings History and Estimates Chart
Kindred Biosciences (NASDAQ KIN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Kindred Biosciences (NASDAQ:KIN) Earnings Estimates
2018 EPS Consensus Estimate: ($1.37)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com
Kindred Biosciences (NASDAQ KIN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 64.36%
Kindred Biosciences (NASDAQ KIN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/16/2018||Raymond Townsend||Director||Sell||2,670||$9.45||$25,231.50||25,057|| |
|3/12/2018||Raymond Townsend||Director||Sell||91||$9.45||$859.95||23,233|| |
|1/2/2018||Raymond Townsend||Director||Sell||6,419||$9.45||$60,659.55||18,419|| |
|7/12/2017||Park West Asset Management Llc||Major Shareholder||Buy||600,000||$7.50||$4,500,000.00|| |
|7/3/2017||Richard Chin||Insider||Sell||13,000||$8.26||$107,380.00||2,297,546|| |
|6/22/2017||Richard Chin||Insider||Sell||13,000||$7.75||$100,750.00||2,310,546|| |
|6/8/2017||Park West Asset Management Llc||Major Shareholder||Buy||15,311||$6.65||$101,818.15|| |
|5/11/2017||Park West Asset Management Llc||Major Shareholder||Buy||155,076||$6.83||$1,059,169.08|| |
|3/15/2017||Park West Asset Management Llc||Major Shareholder||Buy||400,000||$6.60||$2,640,000.00|| |
|3/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||4,200||$6.20||$26,040.00|| |
|3/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||18,066||$6.08||$109,841.28|| |
|1/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||1,690,000||$6.20||$10,478,000.00|| |
|1/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||131,500||$5.30||$696,950.00|| |
|1/6/2017||Park West Asset Management Llc||Major Shareholder||Buy||110,617||$5.10||$564,146.70|| |
|12/16/2016||Park West Asset Management Llc||Insider||Sell||18,000||$4.78||$86,040.00|| |
|12/14/2016||Park West Asset Management Llc||Major Shareholder||Buy||8,334||$4.75||$39,586.50|| |
|12/13/2016||Park West Asset Management Llc||Major Shareholder||Buy||1,148||$4.75||$5,453.00|| |
|12/12/2016||Park West Asset Management Llc||Major Shareholder||Buy||3,112||$4.74||$14,750.88|| |
|3/15/2016||Ernest Mario||Director||Buy||30,000||$3.55||$106,500.00||99,583|| |
|11/23/2015||Raymond Townsend||Director||Buy||2,000||$4.00||$8,000.00||12,000|| |
|11/18/2015||Raymond Townsend||Director||Buy||2,323||$4.78||$11,103.94||10,000|| |
|8/31/2015||Raymond Townsend||Director||Buy||1,677||$5.85||$9,810.45||7,677|| |
|8/14/2015||Raymond Townsend||Director||Buy||3,000||$6.04||$18,120.00|| |
|9/29/2014||Oleg Nodelman||Director||Buy||100,000||$9.56||$956,000.00|| |
|9/3/2014||Ernest Mario||Director||Buy||10,000||$10.55||$105,500.00|| |
|8/28/2014||Oleg Nodelman||Director||Buy||47,000||$10.85||$509,950.00|| |
|8/26/2014||Oleg Nodelman||Director||Buy||85,244||$10.50||$895,062.00|| |
|12/12/2013||Kevin Schultz||Insider||Buy||4,000||$7.00||$28,000.00|| |
|12/12/2013||Oleg Nodelman||Director||Buy||400,000||$7.00||$2,800,000.00|| |
|12/12/2013||Stephen Sundlof||SVP||Buy||1,000||$7.00||$7,000.00|| |
Kindred Biosciences (NASDAQ KIN) News Headlines
|Kindred Biosciences Inc (KIN) Director Raymond Townsend Sells 2,670 Shares|
www.americanbankingnews.com - March 19 at 8:30 PM
|Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference|
finance.yahoo.com - March 8 at 5:05 PM
| Brokerages Expect Kindred Biosciences Inc (KIN) Will Announce Earnings of -$0.38 Per Share|
www.americanbankingnews.com - March 6 at 9:43 AM
|General American Investors Co. Inc. Sells 37,708 Shares of Kindred Biosciences Inc (KIN)|
www.americanbankingnews.com - March 6 at 9:04 AM
|Kindred Biosciences (KIN) Upgraded to Hold at BidaskClub|
www.americanbankingnews.com - March 3 at 5:52 PM
|Kindred Biosciences (KIN) Given a $11.00 Price Target by HC Wainwright Analysts|
www.americanbankingnews.com - March 2 at 11:24 PM
|Kindred Biosciences (KIN) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS|
www.americanbankingnews.com - March 2 at 10:39 AM
|Kindred Biosciences, Inc. to Host Earnings Call|
finance.yahoo.com - March 1 at 4:39 PM
|Kindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - March 1 at 4:39 PM
|Kindred Biosciences Inc (KIN) Forecasted to Post FY2017 Earnings of ($1.21) Per Share|
www.americanbankingnews.com - February 28 at 7:40 AM
|Kindred Biosciences Inc (KIN) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - February 24 at 7:38 PM
|Kindred Biosciences (KIN) Scheduled to Post Earnings on Tuesday|
www.americanbankingnews.com - February 20 at 4:12 AM
| Brokerages Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS|
www.americanbankingnews.com - February 17 at 3:18 PM
|Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results|
finance.yahoo.com - February 15 at 8:54 AM
|Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit|
finance.yahoo.com - February 13 at 9:00 AM
|Reviewing Aduro BioTech (ADRO) and Kindred Biosciences (KIN)|
www.americanbankingnews.com - February 5 at 11:16 AM
|Kindred Biosciences (KIN) Upgraded to "Hold" at ValuEngine|
www.americanbankingnews.com - February 5 at 12:58 AM
|Reviewing G1 Therapeutics (GTHX) and Kindred Biosciences (KIN)|
www.americanbankingnews.com - January 31 at 11:12 PM
|-$0.33 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter|
www.americanbankingnews.com - January 31 at 5:12 PM
|Kindred Biosciences Inc (KIN) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - January 30 at 7:30 PM
|Kindred Biosciences (KIN) Upgraded by Zacks Investment Research to "Hold"|
www.americanbankingnews.com - January 13 at 6:28 PM
|Kindred Biosciences Inc (KIN) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - January 5 at 7:26 PM
|Raymond Townsend Sells 6,419 Shares of Kindred Biosciences Inc (KIN) Stock|
www.americanbankingnews.com - January 4 at 9:50 PM
|Kindred Biosciences (KIN) Research Coverage Started at CL King|
www.americanbankingnews.com - December 27 at 8:09 AM
|Kindred Biosciences (KIN) Given "Hold" Rating at BMO Capital Markets|
www.americanbankingnews.com - December 25 at 1:32 PM
|BRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz|
www.reuters.com - December 21 at 11:30 AM
|Kindred Biosciences (KIN) Reports Submission of European Medicines Agency Filing for Mirataz|
www.streetinsider.com - December 21 at 11:30 AM
|Kindred Biosciences (KIN) Rating Reiterated by Aegis|
www.americanbankingnews.com - December 19 at 8:18 AM
|Kindred Biosciences Inc (KIN) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - December 11 at 9:52 PM
|Zacks: Analysts Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS|
www.americanbankingnews.com - December 11 at 5:26 PM
|Kindred Biosciences (KIN) Given a $11.00 Price Target at B. Riley|
www.americanbankingnews.com - December 5 at 11:22 AM
|Kindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright Analysts|
www.americanbankingnews.com - December 5 at 10:34 AM
|BRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral|
www.reuters.com - December 4 at 11:57 AM
|KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses|
finance.yahoo.com - December 4 at 11:57 AM
|Kindred Biosciences (KIN) Rating Increased to Hold at ValuEngine|
www.americanbankingnews.com - December 3 at 9:36 AM
|Kindred Biosciences, Inc. (KIN) Expected to Earn FY2017 Earnings of ($1.16) Per Share|
www.americanbankingnews.com - November 22 at 6:22 AM
|B. Riley Begins Coverage on Kindred Biosciences, Inc. (KIN)|
www.americanbankingnews.com - November 20 at 7:40 AM
|Kindred Biosciences, Inc. (KIN) Coverage Initiated by Analysts at HC Wainwright|
www.americanbankingnews.com - November 18 at 11:38 AM
|Kindred Biosciences, Inc. (KIN) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - November 16 at 7:50 PM
|Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT|
finance.yahoo.com - November 13 at 11:02 AM
|Kindred Biosciences, Inc. (KIN) Issues Quarterly Earnings Results|
www.americanbankingnews.com - November 8 at 7:11 PM
|Kindred Biosciences Announces Third Quarter 2017 Financial Results|
www.bizjournals.com - November 8 at 11:27 AM
|Kindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per Share|
www.americanbankingnews.com - November 4 at 5:24 PM
|Kindred Biosciences, Inc. (KIN) Set to Announce Earnings on Tuesday|
www.americanbankingnews.com - October 31 at 11:58 AM
|Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - October 22 at 8:38 PM
|Kindred Biosciences to Announce Third Quarter 2017 Financial Results|
finance.yahoo.com - October 11 at 5:05 PM
|Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)|
www.americanbankingnews.com - October 6 at 4:10 PM
|Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference|
finance.yahoo.com - October 6 at 2:37 AM
|Head-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN)|
www.americanbankingnews.com - October 1 at 2:32 AM
|Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - September 27 at 8:44 PM
Kindred Biosciences (NASDAQ:KIN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kindred Biosciences (NASDAQ:KIN) Income Statement, Balance Sheet and Cash Flow Statement
Kindred Biosciences (NASDAQ KIN) Stock Chart for Wednesday, March, 21, 2018